These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32874913)

  • 61. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
    Hu K; Guan WJ; Bi Y; Zhang W; Li L; Zhang B; Liu Q; Song Y; Li X; Duan Z; Zheng Q; Yang Z; Liang J; Han M; Ruan L; Wu C; Zhang Y; Jia ZH; Zhong NS
    Phytomedicine; 2021 May; 85():153242. PubMed ID: 33867046
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study.
    Chen G; Su W; Yang J; Luo D; Xia P; Jia W; Li X; Wang C; Lang S; Meng Q; Zhang Y; Ke Y; Fan A; Yang S; Zheng Y; Fan X; Qiao J; Lian F; Wei L; Tong X
    Front Med; 2020 Dec; 14(6):752-759. PubMed ID: 32926320
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial.
    Cheng LL; Guan WJ; Duan CY; Zhang NF; Lei CL; Hu Y; Chen AL; Li SY; Zhuo C; Deng XL; Cheng FJ; Gao Y; Zhang JH; Xie JX; Peng H; Li YX; Wu XX; Liu W; Peng H; Wang J; Xiao GM; Chen PY; Wang CY; Yang ZF; Zhao JC; Zhong NS
    JAMA Intern Med; 2021 Jan; 181(1):71-78. PubMed ID: 32910179
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The therapeutic efficacy of Xuanfei Baidu Formula combined with conventional drug in the treatment of coronavirus disease 2019: A protocol for systematic review and meta-analysis.
    Li F; Li Y; Zhang J; Li S; Mao A; Zhao C; Wang W; Li F
    Medicine (Baltimore); 2021 Jan; 100(3):e24129. PubMed ID: 33546023
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
    Guo H; Zheng J; Huang G; Xiang Y; Lang C; Li B; Huang D; Sun Q; Luo Y; Zhang Y; Huang L; Fang W; Zheng Y; Wan S
    Ann Palliat Med; 2020 Sep; 9(5):3235-3248. PubMed ID: 32954754
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study.
    Shi N; Liu B; Liang N; Ma Y; Ge Y; Yi H; Wo H; Gu H; Kuang Y; Tang S; Zhao Y; Tong L; Liu S; Zhao C; Chen R; Bai W; Fan Y; Shi Z; Li L; Liu J; Gu H; Zhi Y; Wang Z; Li Y; Li H; Wang J; Jiao L; Tian Y; Xiong Y; Huo R; Zhang X; Bai J; Chen H; Chen L; Feng Q; Guo T; Hou Y; Hu G; Hu X; Hu Y; Huang J; Huang Q; Huang S; Ji L; Jin H; Lei X; Li C; Wu G; Li J; Li M; Li Q; Li X; Liu H; Liu J; Liu Z; Ma Y; Mao Y; Mo L; Na H; Wang J; Song F; Sun S; Wang D; Wang M; Wang X; Wang Y; Wang Y; Wu W; Wu L; Xiao Y; Xie H; Xu H; Xu S; Xue R; Yang C; Yang K; Yang P; Yuan S; Zhang G; Zhang J; Zhang L; Zhao S; Zhao W; Zheng K; Zhou Y; Zhu J; Zhu T; Li G; Wang W; Zhang H; Wang Y; Wang Y
    Pharmacol Res; 2020 Nov; 161():105290. PubMed ID: 33181320
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19.
    Niu W; Wu F; Cui H; Cao W; Chao Y; Wu Z; Fan M; Liang C
    Evid Based Complement Alternat Med; 2020; 2020():7493281. PubMed ID: 33204291
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial.
    Luo Z; Chen W; Xiang M; Wang H; Xiao W; Xu C; Li Y; Min J; Tu Q
    Eur J Integr Med; 2021 Feb; 42():101305. PubMed ID: 33552315
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): A scoping review.
    Luo H; Yang M; Tang QL; Hu XY; Willcox ML; Liu JP
    Eur J Integr Med; 2021 Jan; 41():101251. PubMed ID: 33204368
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.
    Zhang F; Huang J; Liu W; Wang CR; Liu YF; Tu DZ; Liang XM; Yang L; Zhang WD; Chen HZ; Ge GB
    Food Chem Toxicol; 2021 Mar; 149():111998. PubMed ID: 33476691
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China.
    Wang Y; Lu C; Li H; Qi W; Ruan L; Bian Y; Shi H; Song H; Tu S; Zhang Y; Bai T; Cao R; Hong K; Li H; Liu L; Lu S; Rong N; Liu Y; Fang J; Shi J; Yang W; Zhao B; Yang Y; Zhao Y; Li S; Fan T; Rong P; Huang L
    J Ethnopharmacol; 2021 Sep; 277():113888. PubMed ID: 33529638
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.
    Chen X; Wu Y; Chen C; Gu Y; Zhu C; Wang S; Chen J; Zhang L; Lv L; Zhang G; Yuan Y; Chai Y; Zhu M; Wu C
    Acta Pharm Sin B; 2021 Jan; 11(1):222-236. PubMed ID: 33072499
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study.
    Zhang X; Xue Y; Chen X; Wu JM; Su ZJ; Sun M; Liu LJ; Zhang YB; Zhang YL; Xu GH; Shi MY; Song XM; Lu YF; Chen XR; Zhang W; Chen Q
    J Integr Med; 2021 Jan; 19(1):36-41. PubMed ID: 33069626
    [TBL] [Abstract][Full Text] [Related]  

  • 75. "Fei Yan No. 1" as a Combined Treatment for COVID-19: An Efficacy and Potential Mechanistic Study.
    Ai Z; Zhou S; Li W; Wang M; Wang L; Hu G; Tao R; Wang X; Shen Y; Xie L; Ba Y; Wu H; Yang Y
    Front Pharmacol; 2020; 11():581277. PubMed ID: 33132913
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods.
    Zhu YW; Yan XF; Ye TJ; Hu J; Wang XL; Qiu FJ; Liu CH; Hu XD
    J Tradit Complement Med; 2021 Mar; 11(2):180-187. PubMed ID: 33520684
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.
    Remali J; Aizat WM
    Front Pharmacol; 2020; 11():589044. PubMed ID: 33519449
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.
    Xu X; Zhang J; Zheng W; Yang Z; Zhao X; Wang C; Su H; Zhao L; Xue L; Hu F; Xu X; Wen M; Liao J; Zeng Z; Wang L; Zeng J; Guo Y; Li B; Liu Q
    Ann Palliat Med; 2021 May; 10(5):5146-5155. PubMed ID: 33894725
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.
    Xia L; Shi Y; Su J; Friedemann T; Tao Z; Lu Y; Ling Y; Lv Y; Zhao R; Geng Z; Cui X; Lu H; Schröder S
    Phytomedicine; 2021 May; 85():153390. PubMed ID: 33158717
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.
    Ni L; Wen Z; Hu X; Tang W; Wang H; Zhou L; Wu L; Wang H; Xu C; Xu X; Xiao Z; Li Z; Li C; Liu Y; Duan J; Chen C; Li D; Zhang R; Li J; Yi Y; Huang W; Chen Y; Zhao J; Zuo J; Weng J; Jiang H; Wang DW
    Front Med; 2021 Oct; 15(5):704-717. PubMed ID: 33909260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.